Assessment of carbapenems in a mouse model of Mycobacterium tuberculosis infection

Ravindra Jadhav, Ricardo Gallardo-Macias, Gaurav Kumar, Samer S. Daher, Amit Kaushik, Kristina M. Bigelow, Eric L. Nuermberger, Gyanu Lamichhane, Joel S. Freundlich

Research output: Contribution to journalArticlepeer-review


We present further study of a subset of carbapenems, arising from a previously reported machine learning approach, with regard to their mouse pharmacokinetic profiling and subsequent study in a mouse model of sub-acute Mycobacterium tuberculosis infection. Pharmacokinetic metrics for such small molecules were compared to those for meropenem and biapenem, resulting in the selection of two carbapenems to be assessed for their ability to reduce M. tuberculosis bacterial loads in the lungs of infected mice. The original syntheses of these two carbapenems were optimized to provide multigram quantities of each compound. One of the two experimental carbapenems, JSF-2204, exhibited efficacy equivalent to that of meropenem, while both were inferior to rifampin. The lessons learned in this study point toward the need to further enhance the pharmacokinetic profiles of experimental carbapenems to positively impact in vivo efficacy performance.

Original languageEnglish (US)
Article numbere0249841
JournalPloS one
Issue number5 May
StatePublished - May 2021

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Assessment of carbapenems in a mouse model of Mycobacterium tuberculosis infection'. Together they form a unique fingerprint.

Cite this